ArticleFrontiers in molecular medicine2023

Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast.

Howard W Bruckner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.